FDA Approves First Implantable CGM for Diabetics

The FDA’s approval of the first implantable continuous glucose monitor, widely known as an implantable CGM, marked a turning point in diabetes technology. For years, people with diabetes had two basic choices: prick a finger several times a day or wear a short-term sensor on the skin and replace it every week or two. Then came Eversense, a system designed with a tiny glucose sensor placed under the skin by a trained healthcare professional. Suddenly, glucose monitoring was not just wearable. It was, quite literally, under the surface.

For people managing diabetes, that is not a small upgrade. Blood sugar does not politely wait for convenient moments. It rises during meals, drops during workouts, misbehaves during sleep, and sometimes acts like a toddler in a grocery store: unpredictable, dramatic, and very committed to chaos. A continuous glucose monitor helps users see glucose trends in real time, giving them more information than traditional fingerstick testing alone.

The first FDA-approved implantable CGM system, Eversense, was cleared for adults 18 and older with diabetes and originally offered up to 90 days of sensor wear. Since then, the technology has evolved, with later versions offering up to 180 days and, more recently, a one-year implantable CGM option. The big idea remains the same: fewer sensor changes, real-time glucose data, customizable alerts, and a new level of flexibility for people who live with diabetes every day.

What Is an Implantable CGM?

An implantable CGM is a continuous glucose monitoring system that uses a small sensor placed beneath the skin, usually in the upper arm, to measure glucose levels in interstitial fluid. Interstitial fluid is the fluid surrounding the body’s cells. CGMs do not measure glucose directly from the bloodstream the way a traditional fingerstick meter does, but they provide frequent readings and trends that help users understand where their glucose is heading.

In a typical CGM system, a sensor sits under or on the skin, a transmitter sends data, and an app or receiver displays glucose numbers. The implantable version changes the wear-time equation. Instead of replacing a sensor every 10 to 15 days, an implantable sensor may remain in place for months. Newer Eversense technology has extended that idea even further, with Eversense 365 designed for up to one year of continuous glucose monitoring.

Why the FDA Approval Was a Big Deal

The FDA’s approval of the first implantable CGM mattered because it expanded the choices available to people with diabetes. Diabetes management is not one-size-fits-all. Some people love traditional wearable CGMs. Others dislike frequent sensor changes, adhesive irritation, accidental sensor removal, or the feeling that their device is always announcing itself to the world.

An implantable CGM offers a different approach. The sensor stays under the skin, while a removable smart transmitter sits above it. That transmitter can be taken off when needed, such as for certain activities, without wasting the implanted sensor. For anyone who has ever accidentally knocked off a sensor while changing clothes, bumping into a doorframe, or wrestling with a seat belt, that feature may sound less like technology and more like mercy.

How Eversense Works

The Sensor

The Eversense sensor is a small device inserted under the skin of the upper arm during an in-office procedure. The procedure is performed by a trained healthcare provider using local anesthesia. Once placed, the sensor detects glucose changes using fluorescent sensing technology.

The Smart Transmitter

The smart transmitter sits on the skin above the implanted sensor. It powers the sensor wirelessly, receives glucose information, and sends readings to a mobile app. Unlike many CGM transmitters, it is removable and rechargeable. It also provides on-body vibration alerts for high and low glucose events, which can be especially useful when a phone is not nearby or when a user wants discreet alerts.

The Mobile App

The app displays glucose readings, trend arrows, alerts, and historical data. This information helps users and healthcare professionals spot patterns. For example, a person may notice that glucose rises after a certain breakfast, drops during evening walks, or climbs overnight. The app does not magically make diabetes easy, but it does give users a dashboard instead of a guessing game.

What Makes an Implantable CGM Different From Traditional CGMs?

The biggest difference is sensor longevity. Traditional CGMs usually require sensor replacement every several days to two weeks, depending on the device. The original Eversense system extended wear time to 90 days. Eversense E3 later expanded use to up to 180 days. Eversense 365 pushed the category even further with up to one year of sensor wear.

Another major difference is the removable transmitter. With many CGMs, removing the transmitter or sensor means ending that sensor session. With Eversense, the sensor remains implanted while the transmitter can be removed and reattached. That may help during contact sports, formal events, intimate moments, or situations where a user simply wants a break from visible tech.

The system still requires user responsibility. The transmitter must be charged, positioned properly, and worn to receive readings. Calibration may also be required depending on the model and stage of use. Like all diabetes devices, it works best when paired with education, realistic expectations, and guidance from a healthcare professional.

Who May Benefit From an Implantable CGM?

An implantable CGM may be useful for adults with type 1 diabetes or type 2 diabetes who need frequent glucose monitoring, especially those using insulin. CGMs are commonly used by people who want to reduce fingerstick testing, understand glucose trends, detect highs and lows earlier, and make more informed treatment decisions.

People who struggle with adhesive reactions may also be interested in an implantable option. Although the transmitter still uses an adhesive patch, the sensor itself is under the skin and does not need to be replaced every couple of weeks. That difference may matter for people whose skin gets tired of the endless peel-stick-repeat routine.

It may also appeal to people who dislike frequent sensor changes. A person who travels often, works long shifts, exercises regularly, or simply prefers fewer device interruptions may appreciate a long-term sensor. However, it is not the perfect device for everyone. Some people may prefer non-implantable CGMs because they do not require a minor insertion and removal procedure.

Benefits of Continuous Glucose Monitoring

Real-Time Glucose Awareness

A CGM gives users a more complete picture of glucose levels throughout the day and night. Instead of seeing one number at one moment, users can see trends. Is glucose rising quickly? Falling slowly? Holding steady after lunch? That trend information can help users take action earlier.

Alerts for Highs and Lows

Glucose alerts are one of the most practical benefits of CGM technology. Low blood sugar can be dangerous, especially during sleep, exercise, or driving. High blood sugar can also cause problems if it continues unchecked. Alerts can help users respond before a situation becomes more serious.

Better Conversations With Healthcare Providers

CGM data can make medical appointments more productive. Instead of saying, “My numbers have been weird,” users can show time-in-range data, overnight trends, meal responses, and recurring patterns. That gives healthcare providers better information for adjusting medication, insulin dosing, meal planning, or activity routines.

Less Guesswork

Diabetes can feel like trying to solve a puzzle while someone keeps changing the picture on the box. Food, stress, sleep, hormones, illness, medications, and activity can all influence glucose. CGM data helps users connect daily choices with glucose patterns, which can make diabetes feel less mysterious.

Possible Limitations and Risks

An implantable CGM is a medical device, not a magic wand. The sensor must be inserted and removed by a trained healthcare professional. Some users may experience temporary discomfort, bruising, infection risk, skin irritation, or scarring at the insertion site. The transmitter must be worn correctly to collect and send data.

CGMs may also have a delay compared with blood glucose because they measure glucose in interstitial fluid rather than directly in blood. During rapid glucose changes, such as after eating or during intense exercise, readings may lag slightly behind fingerstick values. Users should follow device instructions and use a backup glucose meter when symptoms do not match CGM readings.

Smartphone settings matter too. A CGM alert is only helpful if the user can receive it. Phone updates, notification settings, Bluetooth issues, and low battery can interfere with alerts. In other words, diabetes technology is smart, but it still lives in the real world, where phones die at 3 percent and Bluetooth occasionally decides to become philosophical.

How This Approval Fits Into the Future of Diabetes Care

The FDA approval of the first implantable CGM was part of a larger shift toward more personalized diabetes management. Instead of relying only on occasional blood sugar checks, modern care increasingly focuses on continuous data, time in range, patient preferences, and connected devices.

CGMs can support insulin therapy, lifestyle adjustments, nutrition planning, and safer exercise. Some systems can connect with insulin pumps or automated insulin delivery technology. As diabetes devices improve, the goal is not just better numbers. The goal is less burden, fewer surprises, and more confidence in daily life.

Longer-lasting implantable sensors also raise an important question: How much device maintenance should people with diabetes have to tolerate? Replacing sensors, ordering supplies, fighting insurance paperwork, charging devices, checking apps, and responding to alarms can become exhausting. Longer sensor life may reduce some of that workload, even if it does not eliminate diabetes management itself.

Cost, Insurance, and Access

Access remains one of the biggest issues in diabetes technology. FDA approval does not automatically mean every person can easily get the device. Insurance coverage, provider availability, local training, out-of-pocket costs, and pharmacy or durable medical equipment channels can all affect access.

Some people may qualify for coverage through commercial insurance, Medicare, or other plans, depending on the specific device, diagnosis, insulin use, and medical necessity criteria. Patients interested in an implantable CGM should speak with their diabetes care team and insurance provider to understand eligibility, costs, insertion appointments, and follow-up care.

Practical Questions to Ask Before Choosing an Implantable CGM

Before choosing an implantable CGM, patients may want to ask their healthcare provider several practical questions:

• Am I a good candidate for an implantable CGM?
• How often will the sensor need to be replaced?
• Who performs the insertion and removal procedure?
• What are the risks of insertion?
• Will my insurance cover the device and procedure?
• How often does the system require calibration?
• What should I do if symptoms do not match the CGM reading?
• Can I remove the transmitter for swimming, sports, or special events?

These questions help patients compare an implantable CGM with traditional CGMs and fingerstick monitoring. The best device is not always the newest one. It is the one a person can use consistently, safely, and comfortably.

Real-Life Experiences: What Using an Implantable CGM May Feel Like

For many people, the first experience with CGM technology is eye-opening. Imagine eating a familiar bowl of oatmeal and watching your glucose rise higher than expected. Or taking a walk after dinner and seeing the line flatten like it finally got the memo. These moments can be surprisingly powerful because they turn invisible biology into visible feedback.

An implantable CGM may change the emotional experience, too. Some users may feel relieved that the sensor is not sitting on top of the skin waiting to be bumped, peeled, or caught on clothing. Parents, partners, and caregivers may also feel reassured by glucose alerts and trend data. Diabetes can be lonely, but shared data can make care feel more connected when used thoughtfully.

There can also be an adjustment period. Wearing a transmitter, checking an app, responding to alarms, charging equipment, and trusting a new system takes time. Some people may feel excited during the first week and annoyed by the second. That is normal. Any medical device that joins your daily routine needs to earn its place, preferably without acting like a needy houseplant.

One common experience is learning that glucose is affected by more than food. Stressful meetings, poor sleep, illness, dehydration, caffeine, menstrual cycles, and exercise can all influence glucose patterns. A CGM can reveal these connections. That information may help users make more informed choices, but it can also feel overwhelming at first. Seeing every glucose wiggle does not mean every wiggle needs panic. Sometimes data is just data.

Another experience is learning how to interpret trend arrows. A glucose reading of 110 mg/dL may mean one thing if it is steady and another if it is dropping quickly. Trend arrows add context, and context is where CGMs shine. They help users think ahead instead of reacting late.

People may also appreciate the discretion of vibration alerts. A body-worn vibration can alert the user without loudly announcing a low glucose episode in a quiet room. For students, professionals, performers, or anyone who has ever had a medical device beep at the worst possible moment, discreet alerts can be a meaningful quality-of-life feature.

Still, real-life use includes ordinary frustrations. Adhesive patches may still irritate skin. The transmitter may need repositioning. App settings may need attention. Insurance paperwork may test a person’s patience in ways no glucose curve can explain. Even advanced diabetes technology still depends on human routines, healthcare access, and daily follow-through.

The most valuable experience may be confidence. Not perfection. Not a straight glucose line, because human bodies are not factory machines. Confidence means knowing more, reacting sooner, and having tools that support better decisions. For many adults with diabetes, an implantable CGM represents another step toward living with more information and fewer interruptions.

Conclusion

The FDA approval of the first implantable CGM for diabetics opened a new chapter in diabetes management. By placing a long-term sensor under the skin and pairing it with a removable transmitter and mobile app, Eversense gave people with diabetes another way to monitor glucose continuously. Since the first 90-day system, the technology has progressed to 180-day and one-year options, showing how quickly diabetes care tools continue to evolve.

An implantable CGM is not right for everyone, and it does not replace professional medical guidance. But for adults who want fewer sensor changes, real-time glucose insights, discreet alerts, and a different kind of CGM experience, it may be worth discussing with a healthcare provider. Diabetes still requires daily attention, but better tools can make that attention smarter, calmer, and maybe even a little less annoying.

Note: This article is for informational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified healthcare professional.